Temsirolimus (Torisel) approved by the FDA for the treatment of advanced renal cell carcinoma

Approval was based on data published in The New England Journal of Medicine last week (http://scienceweekly.blogspot.com/2007_05_01_archive.html).

In the US, renal cell carcinoma is diagnosed in approximately 51,000 people per year and accounts for about 85 percent of all U.S. adult kidney cancer. Torisel is manufactured by Wyeth Pharmaceuticals, Inc.


Source: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01644.html